0001354488-14-002331.txt : 20140508 0001354488-14-002331.hdr.sgml : 20140508 20140508083410 ACCESSION NUMBER: 0001354488-14-002331 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20140508 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20140508 DATE AS OF CHANGE: 20140508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Tribute Pharmaceuticals Canada Inc. CENTRAL INDEX KEY: 0001159019 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-31198 FILM NUMBER: 14823127 BUSINESS ADDRESS: STREET 1: 544 EGERTON ST CITY: LONDON STATE: A6 ZIP: N5W 3Z8 BUSINESS PHONE: 519-434-1540 MAIL ADDRESS: STREET 1: 544 EGERTON ST CITY: LONDON STATE: A6 ZIP: N5W 3Z8 FORMER COMPANY: FORMER CONFORMED NAME: STELLAR PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060412 FORMER COMPANY: FORMER CONFORMED NAME: STELLAR INTERNATIONAL INC DATE OF NAME CHANGE: 20010910 8-K 1 tbuff_8k.htm CURRENT REPORT tbuff_8k.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
_____________

FORM 8-K
_____________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 8, 2013
__________________________________________

Tribute Pharmaceuticals Canada Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
 
Ontario, Canada
  
0-31198
  
Not Applicable
(State or other jurisdiction
  
(Commission File Number)
  
(I.R.S. Employer
of incorporation)
      
Identification Number)
 
151 Steeles Avenue East, Milton, Ontario, Canada
(Address of principal executive offices and zip code)
(519) 434-1540
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
Item 7.01              Regulation FD Disclosure
 
On May 8, 2014, Tribute Pharmaceuticals Canada Inc. (the “Company”) issued a press release announcing first quarter 2014 results.  A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
Item 9.01.             Financial Statements and Exhibits.
 
  (d)  
   Exhibits.
   
   99.1  Tribute Pharmaceuticals Canada Inc. Press Release, dated May 8, 2014.
 
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Tribute Pharmaceuticals Canada Inc.
  
       
Date: May 8, 2014
By:
/s/ Scott Langille
  
   
Name: Scott Langille 
  
   
Title Chief Financial Officer
  
       
 
 
 
 
 

3
 
 EX-99.1 2 tbuff_ex991.htm PRESS RELEASE, DATED MAY 8, 2014 tbuff_ex991.htm
EXHIBIT 99.1
 
 
Press Release
Source: Tribute Pharmaceuticals
Canada Inc.
 
Tribute Pharmaceuticals Schedules First Quarter 2014
Financial Results Conference Call

MILTON, ONTARIO--(Marketwired - May 8, 2014) - Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) ("Tribute" or the "Company"), a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare products in Canada and United States, today announced that it will host a conference call on Thursday, May 15, 2014 at 11:00 AM EDT (8:00 AM PST) to review and discuss the Company's results for its first quarter ending March 31, 2014.

To join the conference call, use the dial-in information below. When prompted, ask for the "Tribute Pharmaceuticals Call" and/or be prepared to provide the conference ID.

Date:
05/15/2014
Time:
11:00 AM Eastern
Conference Line Dial-In (Canada & U.S.):
877-407-0782
International Dial-In:
201-689-8567
Conference ID#:
13581986
http://www.investorcalendar.com/IC/CEPage.asp?ID=172736

Dial in at least 10 minutes before the call to ensure timely participation. A playback will be available until 11:59 PM May 29, 2014. To listen to the conference call playback, please call 1-877-660-6853 within Canada and the United States or 1-201-612-7415 if calling internationally.

About Tribute Pharmaceuticals Canada Inc.

Tribute is an emerging Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian and U.S. markets.

Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution 2%), and Collatamp G® (gentamicin-impregnated collagen) in the Canadian market. Additionally, the Company holds an exclusive license for Bezalip® SR in the U.S. and its proprietary products NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships.

For further information on Tribute visit the Company's website: http://www.tributepharma.com.
 
 
1
 

Tribute Pharmaceuticals' Forward Looking Statement

This press release contains certain forward-looking statements about Tribute as defined in the Private Securities Litigation Reform Act of 1995, which statements can be identified by the use of forward-looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. Forward-looking statements, by their nature, are subject to risks and uncertainties, Tribute actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including statements regarding our expectations regarding clinical trials, the timing of clinical results, development timelines and regulatory filings and submissions for our product candidates, general economic conditions, the ability of Tribute to successfully integrate operations, and the timing of expenditures and expansion opportunities, any of which could cause actual results to vary materially from current results or anticipated future results. See Tribute reports filed with the Canadian Securities Regulatory Authorities and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties that could cause actual results to differ materially from results referred to in forward-looking statements. Tribute assumes no obligation to update the information contained in this press release to update forward-looking statements to reflect changed assumptions, the occurrence of anticipated events or changes in future operating results, financial condition or business over time.

Bezalip®SR and Soriatane® are registered trademarks and under license from Actavis Group PTC ehf
Cambia® is a registered trademark and under license from Depomed, Inc.
Collatamp G® is a registered trademark and under license EUSA Pharma (Europe) Limited.

For further information on Tribute, visit http://www.tributepharma.com.

Contact:
Tribute Pharmaceuticals Canada Inc.
Scott Langille
CFO
905-876-3166
scott.langille@tributepharma.com


Investor Relations
Kevin Fickle
President, Nuwa Group LLC
Phone: (925) 330-8315
Email: Kevin@nuwagroup.com
 
2
GRAPHIC 3 logo.jpg begin 644 logo.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HI M'=40L[!5`R23@"L&7Q,LTS0:5:R7L@ZNO"#\:`-^BN?_`.*EN.3]FMP?X1R? MZT\?\)#`,MY,P]!C_P"M0!NT5D0:WB3RKR!H']>U:J.LB!T8,IZ$4`.HHHH` M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H MHHH`*:[K&C.[!549)/0"G5@^("]]@;_"M^T\&WUN!NNX# M]`U=E2EA$O=EX_*J7_"*>'_^ M@/9?]^1710J4(QM5C=G)B*6)G*]&=D<)_P`+=F_Z`Z?]_P`_X4?\+=F_Z`\? M_?\`/^%<9XJ@BM?%.I001K%%',0B(,!1[5ZR-#T.T\*C4&T:REDBLA,0T0^8 MA,\GWKT*U/"THQER7YO,\NA5QE64X^TMR^7_``!?!WC%_%,MVC62V_D*IR)- MV0:;\08[%I#IOA>VA9P-_D,1GTSA:O/\5KZ(9DT,(/5I&']*YJN M!JN?N1LO5?YG90S&E&FE4G=][/\`R/4:*Y'PMXZM?$;R6[P&VO$4N(RVY7`Z MX/\`2LS0OB//K'B"WTQM-CB65RID$I)&`3TQ[5S?5:WO*VVYU_7:#46I?%L> M@T5YQK'Q-GTO6;NP72XY!;RF,.92-V.^,52_X6YJ45R/A7QY:>([@V;P-:W@!94+;E<#K@^OM69P_%"_D MFCC.A8#,%SO;C)_W:Z7Q+XVT[PVP@D5[B\9=PAC.-H]6/:HEA*T9*-M67'&T M)1<^;1'3T5Y;_P`+:NFY314*_P#74G^E;?A7QW<>(M9^PRZ:MNOEL^\.3TQQ MT]ZJ>"K0BY26B\T3#,,/4DHQ>K\F=O1117*=H4444`%%%%`!6)88N/%.J3GG MR(XH%]N-Q_F*VZR-.41:_JZ=-YBE'N"N/YB@"]=:A9V.W[7=0P;_`+OFN%S] M,U&FL:;)]R_M6^DJG^M<#\6H6\O2[@#*!I$/L3@C^1KSVRO#;R`CI7IX?+U6 MI*IS:GC8K-)4*[IN.G<^BHYHIAF*17'JIS3F=47+,%'J37(>`+S[7971SG:R M_P`C6KXKN?LNAO+G'SJ*XI47&K[,]*%=2I>U-4W5N.L\?_?0H2ZMY'")-&S' MH`P)KR>36C_?K2\)7S7OB2!%.0JLS?3%=$L$XQOY=W8O M_>E,9_%2?Z"KM96IMOU328!U,S2'Z*A_J16K7"=Y\^^,O^1PU;_KN:]BO/\` MDG\W_8,/_HNO'?&7_(X:M_UW->Q7G_)/YO\`L&'_`-%U[&,_AT?Z['@8'^)7 M^?ZGFGP[UW3M"U"\EU&?R4DB"J=I;)S[5VFL^/O#,VE7$(E-VTB%1$(CR2/4 MCBN.^'&C:=K.HWL6HVJ7"1PJRAB>#GVK4\?>";;3[%-3TBW$447$\2DG`[-S M^M77C0GBN6=[Z>A&'GB88/F@DXZ^ISG@*TN;GQ7;20*VR#<\K#HJ[2.?KG%) MX*_Y'NP_Z[/_`.@M7<_#?6K2[T673A#%#>6ZY;8H7S5[,?4]C7#>"O\`D>[# M_KL__H+5JZDINLI*UE;\S"-*,%0<7>[O^18O+VWT[XGW%Y=9\B*]9GPN[CZ5 MVUQ\0O"U<7="Q/Q0N1J7E?8_MC^;YOW<8[UV1)(RLO]Z/!Z_I3-:$OA_X@ MS7,\1(2\^T*/[Z%MW%=+3=>2[QT.6+BL/"26TM3W:O$?B%_R/DWTB_D*],B\ M<^&Y;83?VK"@(R5?(8>V*\HUZ^7Q1XV,MA&[K-(D<0QRP&!G'YFN#+J4X5'* M2LK'I9I6IU*48P:;;1[M%_JT^@KQ;7_^2IG_`*_(?_9:]J0;44>@Q7BOB#_D MJ9_Z_(?_`&6HR[XY^C-,U_AP_P`2/:G8(C,>@&:^>6OX+WQ.U_JH>2WDN#), MJ]2N>@_05]#D!E(/0\5X#?68\->,&BOK4300S[_+<<2QD\?I^M7EC5YKK8RS MA2M!]+GH,7Q.\.01+%%9W*1J,*JQ*`!^=:NA>.=*U_4Q8V<-PDI0OF1`!@?C M5""\^'D\*2!=+3<,[9(PK#V(Q6IHTGA)M0`T;^S_`+9M./(`#;>]95(TE%VA M)/S-Z4ZSDKU(M>1TE-#J20""1P:;*^R,FN+T_P`0--?ZC*N0JE66,GJ!P:\R M=10:3ZGM4XIDF-XLT/_A(-`GLUP)A^\A)[..GY]/QKP22.6VG>&9&C ME1BKHPP01VKZ)MI7MG6TNF)/2*4_\M!Z'_:_GUK!\5>!K+Q$3:! MP_LP_K7HX'&*C[D]F>3F6`>(_>4_B7XF+\)W+6FI#T=/Y&MGXCN8_",C`X/G M)_.H?`/AS4?#@U&&_6/$CH8WC;(8`'\1^-7O'6EWFL>&S9V$/FSM,A"[@.`> M3DTJE2#QG.GI=#I4IQR]TVM;/0\0:X8]6/YUZO\`#709+*PDU:Z4I+ML=C8SC[.GMU9S9;ELJ, M#CT/6K:ZG)#J>HQ/#=3JC+L\I-P3Y16DJTY)*3VV,H4*<&W&-K[F9H.AV/AR M>6:PTO4]\JA&\QT88!SZUMRWK3Q/%+I-V\;J592$P0>H^]51=1DB\)PW4DQ\ M^5%02.?XF.,GZ=?PI]E?/+H%WBY\V>V$D9F!SN(!(;\L4I3E-\TG=E0IPA'E MBK(P=/\`"6F:7J"7MGIVKQS(21B5,8/4$9Z4NF^$]*TK5(M0MM+U7SXF++ND M0C)!'3/O6QH]S)+?1I'/:1M] ML6]&8,5&?QQ3=-U)H])O3)<" M[ELMQ,@.=XQN'^'X52Q59*RDQ/!X=N[@BEH>CZ?X>+M8:)>B5QAI7*LQ'IG= MP*M:I:V>M0B/4-`N9POW20H9?H0V15ZPLY62"[GO;B25E#LH?$?(Z!?2J5G* M\VJW'F2:@VRY95V?ZH`8P#63J3@E7' M\ZV='T?3-#73-5^U>8LORN@7*XQQGVK?N5DL;>T6.YG??=1AFD?<2#U M'TI%$NIZA=HUS-#!;.(U2%MI8X!))Z]^E1"I*&L78TJ4H5%::N3_`-I3?]`N M\_)/_BJS=7LK+7(5CU#0;J;;]UL*&7Z$-FKFL3FSTZ*!+HQ23.L2S.W*CJ6S MZX!J!M1EF\*-=1RXG5=K.I_B#8)_SZTHR<7>+LQRC&2M)71S!\`Z%G_D%:N/ M^VJ?XUK>'?">EZ1JGVRULM0@E5"NZXD4K@]N#UKI;\7)T^;['C[1L/EY]:JZ M3)%(DJ++=&5<>9%=$ET/^!]N*UEB:TE9R=C&.$H1?-&"N5]<6*^T^6)+C8W. M&1\%37EUA=-!=E<_>!0_S_I7?>(])NVD-W8,JS8PZ/\`=D'H?0^]>;7\C17K MDQF.:-@9(LY(QUQZ\5XV+OS)V/K,G4'3E%2O?IV-&XU!;NIS7A'AW6 M-5OM1BL]*B^QQLP\V=%+LH]3VKV>QMY([1%:665N[R-EC7IT)N4=CX_,<-[" MJ]5KK8T:***W/.&21)-&4D4,IZ@BH5AGAXCD\Q/[LO4?\"_QJS10`AX7..<5 MSCZMKLI*V^F@'IN93_6NDHH`Y7^P-5U9PVL7S+#G_41'K_3^==%9V5M86ZV] MK$L<:]@.ON?6K%%`!1110!!:6J6D;HC,0TC2'/JQR:;#9I#<7,RLQ:X(+`]L M#'%6:*`*$6DPQPV4.]VCM"2JMCYC@C)^F33FTV(O=LK,HNHPCJN,=",CWP?T MJ[10!473XTN+>968-!$81_M+QU_*H8]%MD>S<[F:TW;"3USZ_CS6C10!0&DP MB&*$NYCCG,^TX^8DDX/MD_I4G]GPB\DN`,>;%Y3ICY6&>I_,BK=%`&?:Z8]H MZ+%?3_9T^["VT@#TSC.*(],>&ZDEBO9E224RM%A2I)Z]LUH44`9UQI(FGEEB MNIH//`698\8?'&>1P<<9%3S6$,NFFQ&4A*!!MZ@"K5%`%>YM$N5A#,P\J19! MCN14$^F;[IKFVN9;:5P!)L`(?'0D$=?>K]%`%3[`KW$$\LC2M"A0;L8).,L? M?BHI-(A>WO(`[HETV]@N/E/'3\JT**`*<=G.L,L;W\SLX&URJ@I],#^=%G8" MVEEGDF>>>4`-(^!P.@`'`ZFKE%`$2G\7U)/>LZD%+1HZ<-6 M=*3DI-?KY'B>J^%]1M-8.EI;2W"!2\#AN63OUX)'YU4T33K2ZUR&ROY7A1F* M,#\I#=@<].:^CI--@E969%)7D$CI5"[\,:=>ONN+2&7_`'T!/YUD\.KW1Z5+ M.9*+A)=-UO?N9?AGP=:Z#)(]JTNR7&Y';<,CN*Z\``8%0VENMK`L2YVJ,#)S MQ4]=$4DK(\>I4E4ES2=V%%%%,@****`"BBB@`HHHH`****`"BBB@`HHHH`** J**`"BBB@`HHHH`****`"BBB@`HHHH`****`"C%%%`!1110`4444`?__9 ` end